Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02921542 · ClinicalTrials.gov registry record
An Evaluation of a Clinical Algorithm With Turbo-Power Following Treatment of Specific Morphologies
A clinical trial, sponsored by Spectranetics Corporation.
- Completed
- Registry status
- 57
- Enrollment target
NCT02921542: Completed study, sponsored by Spectranetics Corporation.
NCT02921542 is a clinical trial that has completed, run by Spectranetics Corporation. The registered enrollment target is 57 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02921542 has completed, sponsored by Spectranetics Corporation.
- COMPLETED
- Registry status
- 57 participants
- Enrollment target
Study Summary
To evaluate vessel lumen quality (gain) and patient outcomes based on treatment with a predetermined laser treatment protocol in patients presenting with varying lesion types or morphologies: homogenous (plaques with a uniform texture-smooth and regular), heterogeneous (plaques with non-uniform texture-smooth and irregular surface), calcific (consisting of calcium) and restenotic (reoccurring narrowing of the vessel following prior treatment) associated with peripheral arterial disease (PAD).
Primary Outcome
1\. Final reduction of stenosis post procedure, determined by angiogram and intravascular ultrasound (IVUS).
Interventions
- DEVICE Laser Atherectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2016-08-15 |
| Est. Completion | 2019-05-01 |
What the finished NCT02921542 record still lists
NCT02921542 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 57 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Laser Atherectomy is the first listed.
NCT02921542 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02921542 about?
NCT02921542 is a clinical study titled "An Evaluation of a Clinical Algorithm With Turbo-Power Following Treatment of Specific Morphologies". To evaluate vessel lumen quality (gain) and patient outcomes based on treatment with a predetermined laser treatment protocol in patients presenting with varying lesion types or morphologies: homogenous (plaques with a uniform texture-smooth and regular), heterogeneous (plaques with non-uniform text...
What is the current status of trial NCT02921542?
This trial is currently completed. The enrollment target is 57 participants. The study started on 2016-08-15. Estimated completion is 2019-05-01.
What interventions are being tested in trial NCT02921542?
The interventions under investigation include: Laser Atherectomy (DEVICE).
Who is sponsoring clinical trial NCT02921542?
This trial is sponsored by Spectranetics Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI